The Pharmaceutical Care Management Association, the leading PBM trade group, said in a statement that it’s “confident the FTC will ultimately conclude that drug manufacturer price setting is the root cause of high drug costs, putting a strain on patients and forcing them to make difficult decisions about their drugs.”
“We are currently reviewing the proposed rule. However, previous point-of-sale proposals in Medicare have not advanced because they would significantly increase Medicare spending,” said JC Scott, president and CEO of the PBM advocacy group Pharmacy Care Management Association in a statement.
Lobbyists and advocates are pressing for a number of changes to a drug pricing overhaul as the focus on a $1.75 trillion budget bill shifts from the House to the Senate.
As a reminder, the U.S. House of Representatives Committee on Oversight and Reform previously found, in a 2021 report, that PBM-negotiated rebates are not correlated with the list prices set by drug companies. The report also finds that “drug companies have
The Pharmaceutical Care Management Association, which represents the Pharmacy Benefit Managers, turned the blame back to manufacturers, noting that the high prices start there. “Ironically, the industry that controls the list price of prescription drugs has attempted to point the finger at those focused on reducing the cost of prescription drugs for patients and payers,” the group said in a statement.
Our national survey of benefit managers and human resources directors, conducted online June 4-9, 2020, consists of 250 respondents drawn from a list of benefit managers and human resources directors provided by Dynata. All respondents work for a company with
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today issued the following statement applauding the Maryland legislature and Governor Larry Hogan for enacting first-of-its-kind legislation, HB 978/SB 915, to increase transparency in the prescription drug supply chain. The legislation,
With the United States in a debate on high drug prices, solutions are being sought that will lower the cost to consumers and taxpayers, while increasing access. However, care must be taken at the federal level to not make changes
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today is announcing new staff additions and a promotion within its State Affairs department. Sam Hallemeier joins PCMA as Director, State Affairs. Sam brings broad industry experience, having worked in both
A recent report from the Massachusetts Health Policy Commission used publicly available drug pricing data in an attempt to identify proxies to highlight the differences between what health plan sponsors reimburse their pharmacy benefit managers (PBM) for a prescription versus
©2024 PCMA. All Rights Reserved.
